Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks

Key Points

• To evaluate the effects of C5 complement inhibitors on disability in NMOSD patients during acute attacks.
• Retrospective analysis of NMOSD patients
• Assessment of disability improvement using complement inhibitors
• Focus on eculizumab and ravulizumab administration timing
• Complement inhibitors linked to improved disability scores
• Treatment administered during or shortly after relapse showed positive effects
• Class IV evidence supports using eculizumab or ravulizumab in acute management

Abstract